Copyright ©The Author(s) 2017.
World J Hepatol. Jan 18, 2017; 9(2): 74-79
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.74
Figure 1
Figure 1 Overview of angiotensin receptor blockers actions on the liver. ARBs reduce hepatic steatosis through favored beta-oxidation and reduced insulin resistance. Concomitantly, it indirectly enhances Mas receptor activity, eliciting hepatoprotective effects by low TGF-beta1 expression, which limits hepatic stellate cells activation and prevents liver fibrosis. ARBs: Angiotensin receptor blockers; TGF-beta1: Transforming growth factor-beta 1.